Disc Medicine CEO John Quisel describes the process of becoming among the first companies to receive FDA's new Commissioner's National Priority Voucher (CNPV)

He describes how Disc applied for and was awarded a CNPV for Bitopertin, which treats a rare disease that causes extreme sensitivity to sunlight. Plus, quickly ramping up a commercial team, and discussing Disc's two other development programs.

Episode metadata supplied by the publisher feed · Published Oct 22, 2025

Embed this episode

Attribution link and audio player

Ready to play

Disc Medicine CEO John Quisel describes the process of becoming among the first companies to receive FDA's new Commissioner's National Priority Voucher (CNPV)

0:00 23:10

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BiotechTV - News?

This episode is 23 minutes long.

When was this BiotechTV - News episode published?

This episode was published on October 22, 2025.

Can I download this BiotechTV - News episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!